A physician reported that a (b)(6)y/o female received deflux (dextranomer microspheres/hyaluronic acid) injection into the submucosa of the urinary bladder as treatment for grade 4 vesicoureteral reflux on the left and grade 2/3 reflux on the right.Add'l medical history and concurrent medications were not provided.On (b)(6) 2014, the pt received deflux.She was injected with 0.8 cc on each side.The day after deflux insertion, the pt was doing well according to her mother.On (b)(6) 2014, the pt underwent a renal ultrasound as routine f/u to the procedure.The ultrasound showed severe left hydronephrosis grade 4 dilatation and moderate hydroureter extending down to 1.5 cm deflux injection site mass protruding into the bladder at the left vesicoureteral insertion.The pt's right side was normal.On (b)(6) 2014, the pt was evaluated by the physician.On (b)(6) 2014, the pt was scheduled to undergo a cystoscopy and left stent placement.The physician felt the events were possibly related to deflux.The company assessed the events as possibly related to deflux.
|